BillionToOne, Inc. - Class A common stock (BLLN)
90.81
-0.73 (-0.80%)
NASDAQ · Last Trade: Nov 19th, 3:42 PM EST
Detailed Quote
| Previous Close | 91.54 |
|---|---|
| Open | 90.85 |
| Bid | 90.72 |
| Ask | 90.89 |
| Day's Range | 89.51 - 93.79 |
| 52 Week Range | 61.96 - 150.44 |
| Volume | 727,772 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 675,679 |
Chart
News & Press Releases
Investors who lost money on BillionToOne, Inc. ("BillionToOne" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of BillionToOne, Inc. (NASDAQ: BLLN) investors into whether the Company may have violated the federal securities laws. The investigation follows the November 18, 2026 disclosure regarding BillionToOne, Inc.
By Glancy Prongay Wolke & Rotter LLP · Via Business Wire · November 19, 2026
Investors who suffered losses on BillionToOne, Inc. ("BillionToOne" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of BillionToOne, Inc. (NASDAQ: BLLN) investors into whether the Company may have violated the federal securities laws. The investigation comes after a November 18, 2026 disclosure concerning BillionToOne, Inc.
By The Law Offices of Howard G. Smith · Via Business Wire · November 19, 2026
Shares of BillionToOne, Inc. (“BillionToOne”) fell over 6% on November 18, 2026, after Fuzzy Panda Research published a report alleging that the company is the subject of an undisclosed state Medicaid fraud investigation and has engaged in improper billing practices. Gibbs Mura is investigating a potential BillionToOne (NASDAQ: BLLN) Securities Class Action Lawsuit concerning whether BillionToOne has violated federal securities laws by providing false or misleading statements to investors.
By Gibbs Mura · Via Business Wire · November 18, 2026
BillionToOne Inc Cl A (NASDAQ:BLLN) Tops Q3 2026 Estimates and Raises Revenue Outlookchartmill.com
Via Chartmill · November 4, 2026
BillionToOne (NASDAQ:BLLN) Shares Tumble After Q2 Profit Misses Estimateschartmill.com
Via Chartmill · August 5, 2026
BillionToOne, Inc. ("BillionToOne" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential securities fraud claims on behalf of investors in BillionToOne, Inc. (NASDAQ: BLLN), examining whether the Company may have violated the federal securities laws. The investigation centers on the disclosure about BillionToOne, Inc. on November 18, 2026.
By The Law Offices of Frank R. Cruz · Via Business Wire · November 18, 2026
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company today responded to a report published on November 18, 2026 by Fuzzy Panda Research, a short seller that, by its own disclosure, holds a short position in BillionToOne securities and stands to profit from driving down the company’s stock price.
By BillionToOne, Inc. · Via GlobeNewswire · November 18, 2026
Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of BillionToOne, Inc. (NASDAQ: BLLN) resulting from allegations that BillionToOne may have issued materially misleading business information to the investing public.
By The Rosen Law Firm, P.A. · Via Business Wire · November 18, 2026
MENLO PARK, Calif., Nov. 18, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Piper Sandler 38th Annual Healthcare Conference.
By BillionToOne, Inc. · Via GlobeNewswire · November 18, 2026
Gross margin held at 71% while cost per test stayed near $169, a sign that growth is not being bought with debt.
Via The Motley Fool · November 15, 2026
Record revenue, a fifth profitable quarter, and a December cancer test launch.
Via The Motley Fool · November 5, 2026
Billiontoone (NASDAQ:BLLN) raised its full-year revenue outlook after third-quarter sales rose 47% from a year earlier, driven by growth in both prenatal and oncology testing. The molecular diagnostics company also reported its fifth consecutive quarter of positive GAAP operating income.
Revenue fo
Via MarketBeat · November 4, 2026
MENLO PARK, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2026 and raised guidance for full year 2026.
By BillionToOne, Inc. · Via GlobeNewswire · November 4, 2026
MENLO PARK, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company will participate in two upcoming investor conferences.
By BillionToOne, Inc. · Via GlobeNewswire · October 27, 2026
MENLO PARK, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026 after the market close on Wednesday, November 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.
By BillionToOne, Inc. · Via GlobeNewswire · October 14, 2026
Head-to-head comparison shows 94% concordance with tumor-informed ctDNA testing, with the clinical ground-truth in all discordant cases supporting Northstar Response
By BillionToOne, Inc. · Via GlobeNewswire · October 7, 2026
John Roderick Ten Bosch sold shares on Sept. 9, maintaining a direct stake worth ~$2.4 million.
Via The Motley Fool · September 21, 2026
The medical diagnostics company disclosed a substantial insider stock sale.
Via The Motley Fool · September 17, 2026
The molecular diagnostics company reported a notable insider stock sale.
Via The Motley Fool · August 28, 2026
Oncology tests surged 176% while prenatal revenue climbed 55%, driving 64% overall growth.
Via The Motley Fool · August 12, 2026
Top stock movements in today's session.chartmill.com
Via Chartmill · August 6, 2026
Let's have a look at the top gainers and losers in the middle of the day of today's session.chartmill.com
Via Chartmill · August 6, 2026
Let's uncover which stocks are experiencing notable gaps during today's session.chartmill.com
Via Chartmill · August 6, 2026
Which stocks are moving before the opening bell on Thursday?chartmill.com
Via Chartmill · August 6, 2026
Billiontoone (NASDAQ:BLLN) reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reit
Via MarketBeat · August 5, 2026